Published in Expert Rev Respir Med on April 01, 2011
Identification of Rare Variants in ATP8B4 as a Risk Factor for Systemic Sclerosis by Whole-Exome Sequencing. Arthritis Rheumatol (2016) 1.41
A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol (2012) 1.18
Systemic sclerosis-associated pulmonary arterial hypertension. Chest (2013) 1.00
Improving outcomes for pulmonary vascular disease. Am J Respir Crit Care Med (2012) 0.92
Sex differences in response to tadalafil in pulmonary arterial hypertension. Chest (2015) 0.85
Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension. Pulm Circ (2015) 0.79
Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans. Medicine (Baltimore) (2014) 0.78
Prevalence of Pulmonary Arterial Hypertension in Korean Adult Patients with Systemic Sclerosis: Result of a Pilot Echocardiographic Screening Study. J Cardiovasc Ultrasound (2016) 0.75
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol (1988) 16.45
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med (2006) 6.06
Criteria for the classification of early systemic sclerosis. J Rheumatol (2001) 5.39
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med (1993) 4.91
Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis (2007) 4.88
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol (2002) 4.79
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest (2009) 4.08
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med (2000) 4.07
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med (2002) 3.91
Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum (2003) 3.84
Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med (1995) 3.70
Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med (2008) 3.67
Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med (2006) 3.59
Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med (2000) 3.57
Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum (2005) 3.44
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med (2001) 3.29
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med (2008) 3.13
Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum (2000) 3.02
Tadalafil therapy for pulmonary arterial hypertension. Circulation (2009) 2.98
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation (2005) 2.98
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85
Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J (2005) 2.82
Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 2.74
Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med (2005) 2.69
Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med (2003) 2.64
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol (2010) 2.55
Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest (2006) 2.43
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J (2006) 2.34
Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med (2004) 2.29
Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med (1990) 2.25
Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med (2008) 2.22
Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med (1999) 2.21
Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology (2001) 2.20
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J (2006) 2.16
Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum (2006) 2.04
The right ventricle in pulmonary hypertension. Coron Artery Dis (2005) 2.03
Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J (2009) 2.01
Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum (2003) 1.94
The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum (2005) 1.91
Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest (2003) 1.90
High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum (2008) 1.90
Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. J Rheumatol (2007) 1.87
Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J (2009) 1.85
Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis (2010) 1.83
Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2005) 1.82
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J (2006) 1.79
Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol (2003) 1.79
Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol (2009) 1.78
Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol (2006) 1.73
Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis (2007) 1.72
Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest (2004) 1.72
Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum (1986) 1.72
Scleroderma epidemiology. Rheum Dis Clin North Am (2003) 1.70
Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med (2010) 1.69
Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum (2007) 1.67
Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am (1996) 1.57
Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res (2002) 1.52
Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med (2010) 1.50
Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum (1985) 1.45
Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 1.44
Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol (2007) 1.42
Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum (2008) 1.40
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum (2009) 1.40
Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 1.38
Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum (2003) 1.37
Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum (2001) 1.36
Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum (2007) 1.33
Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum (2000) 1.33
Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum (1992) 1.33
Long term imatinib treatment in pulmonary arterial hypertension. Thorax (2006) 1.32
Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest (2006) 1.29
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol (2005) 1.29
Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res (2008) 1.27
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis (2007) 1.27
Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J (2006) 1.23
Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med (2006) 1.22
Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis (2010) 1.22
The many faces of scleroderma. Rheum Dis Clin North Am (2008) 1.22
Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest (2008) 1.21
Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med (1999) 1.18
Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol (2010) 1.17
Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum (2000) 1.17
Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum (2005) 1.16
Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum (1997) 1.14
Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol (1995) 1.12
Racial differences in scleroderma among women in Michigan. Arthritis Rheum (1997) 1.10
Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol (2009) 1.10
Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum (2003) 1.10
Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant (2005) 1.09
Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest (1996) 1.09
Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol (1997) 1.09
Autoantigens in systemic autoimmunity: critical partner in pathogenesis. J Intern Med (2009) 1.07
Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur Respir J (2008) 1.06
Genetics and mediators in pulmonary arterial hypertension. Clin Chest Med (2007) 1.06
Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax (2005) 1.03
Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med (2009) 3.96
Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med (2006) 3.59
Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med (2004) 3.59
Endothelial dysfunction in pulmonary hypertension. Circulation (2004) 2.82
Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am J Respir Crit Care Med (2004) 2.73
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation (2013) 2.64
Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. J Rheumatol (2011) 2.48
Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest (2010) 2.35
Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation (2009) 2.17
Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum (2006) 2.04
Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. Ann Am Thorac Soc (2015) 2.02
Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation (2011) 1.92
Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation (2011) 1.91
Use of consomic rats for genomic insights into ventilator-associated lung injury. Am J Physiol Lung Cell Mol Physiol (2007) 1.86
Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol (2009) 1.78
PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail (2008) 1.75
Epidermal growth factor receptor (EGFR) regulates mechanical ventilation-induced lung injury in mice. Transl Res (2008) 1.57
Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest (2008) 1.57
Modulation of inducible nitric oxide synthase by hypoxia in pulmonary artery endothelial cells. Am J Respir Cell Mol Biol (2002) 1.55
Disruption of Nrf2 impairs the resolution of hyperoxia-induced acute lung injury and inflammation in mice. J Immunol (2009) 1.53
Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 1.44
Mechanical stress activates xanthine oxidoreductase through MAP kinase-dependent pathways. Am J Physiol Lung Cell Mol Physiol (2006) 1.42
Genetic and pharmacologic evidence links oxidative stress to ventilator-induced lung injury in mice. Am J Respir Crit Care Med (2007) 1.41
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum (2009) 1.40
Cytoskeletal changes in hypoxic pulmonary endothelial cells are dependent on MAPK-activated protein kinase MK2. J Biol Chem (2002) 1.40
Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 1.38
Inducible nitric oxide synthase contributes to ventilator-induced lung injury. Am J Respir Crit Care Med (2005) 1.35
Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol (2003) 1.34
Regulation of endothelial barrier function by reactive oxygen and nitrogen species. Microvasc Res (2008) 1.34
Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling. Am J Pathol (2010) 1.33
Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol (2007) 1.30
Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res (2008) 1.27
Activation of the STAT pathway in acute lung injury. Am J Physiol Lung Cell Mol Physiol (2004) 1.25
Mitogen activated protein kinase activated protein kinase 2 regulates actin polymerization and vascular leak in ventilator associated lung injury. PLoS One (2009) 1.24
Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension. Circ Heart Fail (2013) 1.21
Soluble guanylyl cyclase contributes to ventilator-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol (2008) 1.18
Hypoxia alters biophysical properties of endothelial cells via p38 MAPK- and Rho kinase-dependent pathways. Am J Physiol Cell Physiol (2005) 1.18
Myocardial delayed enhancement in pulmonary hypertension: pulmonary hemodynamics, right ventricular function, and remodeling. AJR Am J Roentgenol (2011) 1.15
Resistin-like molecule-beta in scleroderma-associated pulmonary hypertension. Am J Respir Cell Mol Biol (2009) 1.12
Redox imbalance and ventilator-induced lung injury. Antioxid Redox Signal (2007) 1.10
Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant (2005) 1.09
Innate immunity against bacterial infection following hyperoxia exposure is impaired in NRF2-deficient mice. J Immunol (2009) 1.09
Activated protein C protects against ventilator-induced pulmonary capillary leak. Am J Physiol Lung Cell Mol Physiol (2009) 1.09
Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report. Am J Respir Crit Care Med (2010) 1.09
Vascular receptor autoantibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med (2015) 1.08
Alveolar cell apoptosis is dependent on p38 MAP kinase-mediated activation of xanthine oxidoreductase in ventilator-induced lung injury. J Appl Physiol (1985) (2008) 1.08
Trials and Tribulations of Therapies for the Acute Respiratory Distress Syndrome. Crit Care Med (2016) 1.07
Protective role of PI3-kinase/Akt/eNOS signaling in mechanical stress through inhibition of p38 mitogen-activated protein kinase in mouse lung. Acta Pharmacol Sin (2010) 1.06
The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice. Am J Respir Crit Care Med (2009) 1.05
One hundred years of research in the pathogenesis of pulmonary hypertension. Am J Respir Cell Mol Biol (2005) 1.05
Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis (2012) 1.03
Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 1.03
EGFR-activated signaling and actin remodeling regulate cyclic stretch-induced NRF2-ARE activation. Am J Respir Cell Mol Biol (2006) 1.02
Xanthine oxidoreductase in respiratory and cardiovascular disorders. Am J Physiol Lung Cell Mol Physiol (2008) 1.02
An official American Thoracic Society Statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med (2014) 1.02
Portopulmonary hypertension: a tale of two circulations. Chest (2003) 1.00
p53 mediates cigarette smoke-induced apoptosis of pulmonary endothelial cells: inhibitory effects of macrophage migration inhibitor factor. Am J Respir Cell Mol Biol (2010) 1.00
Systemic sclerosis-associated pulmonary arterial hypertension. Chest (2013) 1.00
Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension. Radiology (2010) 0.99
Pulmonary artery measurements in pulmonary hypertension: the role of computed tomography. J Thorac Imaging (2013) 0.98
Resolution of experimental lung injury by monocyte-derived inducible nitric oxide synthase. J Immunol (2012) 0.97
Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J (2012) 0.96
A critical role for the protein apoptosis repressor with caspase recruitment domain in hypoxia-induced pulmonary hypertension. Circulation (2011) 0.96
Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest (2014) 0.96
Pulmonary arterial hypertension: MR imaging-derived first-pass bolus kinetic parameters are biomarkers for pulmonary hemodynamics, cardiac function, and ventricular remodeling. Radiology (2012) 0.95
Scleroderma lung disease. Clin Rev Allergy Immunol (2011) 0.93
Cardiac complications of systemic sclerosis: recent progress in diagnosis. Curr Opin Rheumatol (2010) 0.92
Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. J Clin Microbiol (2002) 0.92
Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. Am J Respir Crit Care Med (2015) 0.91
Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum (2011) 0.91
Regional and global biventricular function in pulmonary arterial hypertension: a cardiac MR imaging study. Radiology (2012) 0.91
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med (2004) 0.90
Increased right ventricular Septomarginal trabeculation mass is a novel marker for pulmonary hypertension: comparison with ventricular mass index and right ventricular mass. Invest Radiol (2011) 0.90
Upregulation of xanthine oxidase by tobacco smoke condensate in pulmonary endothelial cells. Toxicol Appl Pharmacol (2003) 0.89
Differential gene expression in chronic hypoxic pulmonary hypertension: effect of simvastatin treatment. Chest (2005) 0.87
Mitogen-activated protein kinase-activated protein kinase 2 mediates apoptosis during lung vascular permeability by regulating movement of cleaved caspase 3. Am J Respir Cell Mol Biol (2014) 0.87
Pulmonary endothelial cell NOX. Am J Respir Cell Mol Biol (2012) 0.87
Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin (2012) 0.86
Erythroid-specific transcriptional changes in PBMCs from pulmonary hypertension patients. PLoS One (2012) 0.85
Macrophage migration inhibitory factor is a novel determinant of cigarette smoke-induced lung damage. Am J Respir Cell Mol Biol (2014) 0.85
Xanthine oxidoreductase is a critical mediator of cigarette smoke-induced endothelial cell DNA damage and apoptosis. Free Radic Biol Med (2013) 0.85
Estrogen modulates xanthine dehydrogenase/xanthine oxidase activity by a receptor-independent mechanism. Antioxid Redox Signal (2003) 0.82
Right ventricular dysfunction in chronic lung disease. Cardiol Clin (2012) 0.82
Therapy for pulmonary arterial hypertension associated with systemic sclerosis. Curr Opin Rheumatol (2009) 0.80
Right ventricle dysfunction in pulmonary hypertension: mechanisms and modes of detection. Curr Opin Pulm Med (2015) 0.79
Real-time single-heartbeat fast strain-encoded imaging of right ventricular regional function: normal versus chronic pulmonary hypertension. Magn Reson Med (2010) 0.79
Interleukin-6 and tumor necrosis factor-α are associated with quality of life-related symptoms in pulmonary arterial hypertension. Ann Am Thorac Soc (2015) 0.79
Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans. Medicine (Baltimore) (2014) 0.78
N-terminal brain natriuretic peptide in scleroderma-associated pulmonary arterial hypertension. Eur Heart J (2006) 0.78
Severe respiratory muscle weakness related to long-term colchicine therapy. Respir Care (2004) 0.77
Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest (2010) 0.77
Pulmonary hypertension due to lung disease and/or hypoxia. Clin Chest Med (2013) 0.77
Drumming up prognostic significance in a heartbeat in pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 0.77
Linking new and old concepts: inflammation meets the Warburg phenomenon in pulmonary arterial hypertension. J Mol Med (Berl) (2011) 0.76
Survival in systemic sclerosis-related pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med (2009) 0.75
Moving beyond the "Allegory of the Cave" in the assessment of pulmonary arterial hypertension. J Appl Physiol (1985) (2011) 0.75
Drs. Mathai and Hassoun reply. J Rheumatol (2013) 0.75
Pulmonary Arterial Compliance in Acute Respiratory Distress Syndrome: Clinical Determinants and Association With Outcome From the Fluid and Catheter Treatment Trial Cohort. Crit Care Med (2016) 0.75
Prediction of pulmonary artery pressure. Chest (2005) 0.75
Inflammatory mechanisms in the pathogenesis of pulmonary arterial hypertension. Compr Physiol (2011) 0.75